Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin. Different doses and dosing frequencies will be investigated
Metastatic Breast Cancer
DRUG: POL6326
Safety and tolerability of POL6326 in combination with eribulin in patients with metastatic breast cancer, Incidence and severity of adverse events and serious adverse events of the combination of POL6326 and eribulin when compared to the adverse event profile of eribulin alone, 6 months
Response rate of treatment with POL6326 and eribulin in patients with metastatic breast cancer, Determination of the complete response (CR) and partial response (PR) in patients treated with the combination of POL6326 and eribulin, 12-24 months
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin. Different doses and dosing frequencies will be investigated